The Peptide NewsroomPeptide research, industry and supply-chain headlines

Ten-Vendor Audit Ranks Peptide Sellers on Paperwork, Not Price

Photograph: Pills Medicine
Photo: "Pills Medicine" by Martin Vorel is marked with CC0 1.0. Source: https://stocksnap.io/photo/pills-medicine-TPI078T0IS

A ten-vendor audit published by Where To Buy Peptides scored research-peptide suppliers on four things a buyer can verify before paying, and its top finding is about documentation rather than cost. Its verdict on the winner is blunt: "Peptriva is the best peptide vendor we could find during our research."

The four criteria were whether a third-party certificate of analysis exists and opens, whether the testing lab is named in the vendor's own site copy, whether the certificate matches the lot actually shipped, and price per milligram. The audit reports that eight of the ten publish a certificate that opens without an email gate, and that only three name their lab anywhere a buyer would see it without opening a PDF.

Where the field falls down

That gap between publishing a document and naming who wrote it is the most useful thing in the data. A certificate with an unfamiliar letterhead is not nothing, but it asks the reader to do work almost nobody does, and vendors know it.

The audit names Freedom Diagnostics on Peptriva's product page, MZ Biolabs and Colmaric for Sports Technology Labs, and Janoshik for Swiss Chems. The remaining seven leave the lab inside the document or do not publish one at all.

Price and diligence move separately

The pricing spread is where the audit gets genuinely interesting. Across the vendors that publish a certificate, BPC-157 ran from $7.50 to $12.45 per milligram, and the most expensive row carries a certificate the audit describes as roughly two years stale.

Cheaper still is a vendor with no published certificate at all, at $6.90. Those two facts sit next to each other for a reason: paying more is not buying more paperwork, and paying less is sometimes buying none.

What the ranking leaves open

The audit dates its figures, which is the right instinct in a market where prices move monthly, and nine of its ten rows were checked on 13 August. That is a real limitation on any ranking built from them, and the checks themselves outlive the table.

Where To Buy Peptides states that it earns a commission on purchases made through its links.

Source: Where To Buy Peptides. Read the original.

Filed under: safety, supply

Comments (0)

Native comments are not enabled on this site yet. Set GISCUS_REPO to turn them on. Until then the Reddit thread above is the discussion venue.

More from The Peptide Newsroom

GLP-1 Use Linked to Lower Hospitalization and Death in Dialysis Patients, But the Design Is Retrospective

A matched retrospective cohort study in the Clinical Journal of the American Society of Nephrology reports that GLP-1RA use was independently associated with lower hospitalization and mortality rates among patients starting in-center hemodialysis. The effect sizes are modest, the design cannot establish cause, and the authors say so.

FAERS Analysis Flags Gastric Emptying Signal for Five GLP-1 Drugs, But Authors Say It Is Not Risk

A signal-detection analysis indexed by Europe PMC reports that all five GLP-1 receptor agonists it examined met conventional signal criteria for impaired gastric emptying in FAERS. The authors state the work is descriptive and hypothesis-generating and makes no claim about clinical risk.

All Nine GLP-1 Products Hit a Gastric Emptying Reporting Signal, But Authors Say Causation Is Unproven

A signal-detection analysis of the FDA Adverse Event Reporting System reports that all nine marketed GLP-1 receptor agonist products met conventional criteria for a disproportionate reporting signal for impaired gastric emptying. The authors state the analysis is descriptive and hypothesis-generating and makes no claim about clinical risk.